The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.
Investigators identified dozens of Alzheimer's-related epigenetic signatures based on cytosine methylation and other profiles in Alzheimer's-related cell lines and patient samples.